A/S, a global healthcare giant specializing in diabetes care and obesity treatment, continues to dominate the GLP-1 drug market alongside competitor Eli Lilly (NYSE:LLY). With a market capitalization ...

Metsera (MTSR), which is developing ultra-long-acting drugs for the treatment of obesity, has set terms for an upsized $275M initial public offering. Read more here.

Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it ...

Stocks to Buy or Sell. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other ...

Akero Therapeutics shares traded near their all-time high as the drugmaker reported positive results in a study of its treatment for liver disease.

Veru said on Monday its experimental drug in combination with Novo Nordisk's weight-loss treatment Wegovy, helped preserve muscle in older patients with obesity, meeting the main goal of a mid-stage ...

Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were taking Wegovy ...

An investigational drug from Veru helped preserve lean mass in patients taking Wegovy, though some experts raised questions ...

The pharmacy association said it was worried some patients were accessing the drugs inappropriately amid a surge in demand.View on euronews ...

The gaming industry is larger than the film and music industries combined. A growing subgenre is the "cozy game," meant to ...

On Friday, the Danish pharma giant released the stellar results from a phase 1/2 trial for a once-weekly jab in its pipeline.